Millions of patients carry a diagnosis of treatment-resistant hypertension — a label implying the cardiovascular system has defied multiple medications. But a growing body of evidence suggests that label is frequently wrong, and the implications for both clinical practice and long-term heart health are significant. If the resistance is pharmacological illusion rather than biological reality, the path forward looks very different.
This review, synthesizing recent literature on apparent resistant hypertension, confronts a striking discrepancy: when objective therapeutic drug monitoring is applied to patients presumed to be medication-resistant, somewhere between one in four and four in five are found to be non-adherent to their prescribed regimen. A substantial subset show no detectable drug in their system at all. Critically, neither clinician intuition nor patient self-report reliably identifies this gap — the subjective assessment fails on both sides of the clinical encounter. The review further highlights that single-pill combination therapies consistently outperform multi-pill free equivalents in adherence and persistence metrics, and observational data links these formulations to improved cardiovascular endpoints. Meanwhile, emerging agents targeting the aldosterone and endothelin pathways show meaningful blood pressure reductions in genuinely resistant cases, though limited availability makes adherence confirmation all the more essential before escalating to these newer pharmacological options.
The clinical and public health stakes here deserve emphasis. Resistant hypertension is associated with substantially elevated risks of stroke, myocardial infarction, and renal failure. If up to 80% of apparent cases reflect adherence failure rather than true biological resistance, then aggressive pharmacological intensification — with attendant cost, side-effect burden, and polypharmacy risk — may be both unnecessary and harmful for a large patient population. The finding that clinicians cannot reliably detect non-adherence by clinical impression alone challenges a deeply embedded assumption in routine practice. This review is confirmatory rather than paradigm-shifting in isolation, but its synthesis reinforces an underappreciated structural problem: the healthcare system systematically misclassifies adherence failure as treatment failure, with real consequences for patient outcomes. Regimen simplification, cost reduction, and objective monitoring warrant broader adoption as first-line diagnostic and therapeutic steps.